Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Immunotherapy has revolutionized cancer treatment. In non-small-cell lung cancer (NSCLC), monotherapy with immune checkpoint inhibitors has improved survival in metastatic disease. Combinations of immune checkpoint inhibitors have shown synergy in preclinical models and are being studied as part of...

Full description

Bibliographic Details
Main Authors: Sonam Puri, Michael Shafique
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2020-01-01
Series:Drugs in Context
Subjects:
anti-ctla-4
anti-pd-1/pdl-1
lung cancer
Online Access:https://www.drugsincontext.com/combination-checkpoint-inhibitors-for-treatment-of-non-small-cell-lung-cancer:-an-update-on-dual-anti-ctla-4-and-anti-pd-1-pd-l1-therapies/

Internet

https://www.drugsincontext.com/combination-checkpoint-inhibitors-for-treatment-of-non-small-cell-lung-cancer:-an-update-on-dual-anti-ctla-4-and-anti-pd-1-pd-l1-therapies/

Similar Items